Beata N.
- Country
- Poland
- Department
- N/A
Research Overview
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
- Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of Oral MH002 (10 000 vs 40 000 million CFU) in Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled with 5‑ASA
- Long-term Safety and Efficacy Evaluation of Obefazimod (ABX464) in Moderate to Severe Ulcerative Colitis: A Phase II Open-label Study
Data & Insights
Has run more than one trial at 163 of 317 partner sites.
Specializations
Inflammatory Bowel Disease
This investigator specializes in treating moderate to severe ulcerative colitis, conducting research on innovative therapeutic approaches for managing inflammatory bowel conditions.
- Ulcerative Colitis Management
- Long-term Treatment Strategies
- Novel Therapeutic Agents
Their expertise extends to evaluating treatment responses in patients with refractory ulcerative colitis.
Crohn's Disease Research
The investigator focuses on developing treatments for moderately to severely active Crohn's disease, particularly examining therapeutic options for patients with inadequate response to conventional treatments.
- Induction Therapy Development
- Maintenance Treatment Protocols
- Advanced Therapy Assessment
Their work encompasses evaluating both short-term and sustained clinical responses in Crohn's disease patients.
Otology
The investigator conducts research in treating idiopathic sudden sensorineural hearing loss, exploring alternative treatment methods to traditional oral steroid therapy.
- Middle Ear Therapeutics
- Hearing Loss Treatment
- Audiometric Outcomes
Their research includes evaluation of novel therapeutic approaches for hearing threshold improvement.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.